SUPRIYA logo
SUPRIYA
Supriya Lifescience

Expansion Into Regulated Markets And CMO/CDMO Opportunities To Strengthen Future Prospects

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 1 Analyst
Published
11 Feb 25
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
₹843.00
20.1% undervalued intrinsic discount
31 Jul
₹673.40
Loading
1Y
69.6%
7D
0.3%

Author's Valuation

₹843.0

20.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates8

Shared on01 May 25
Fair value Increased 9.41%

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 4.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on13 Mar 25
Fair value Decreased 12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more